Home » GENVEC GETS CONTRACT EXTENSION OF HIV VACCINE DEVELOPMENT WORK
GENVEC GETS CONTRACT EXTENSION OF HIV VACCINE DEVELOPMENT WORK
GenVec (GNVC) has received a $10 million one-year contract extension of its HIV vaccine development work with the Vaccine Research Center, part of the NIH's National Institute of Allergy and Infectious Diseases. In a press release, the biopharmaceutical company said the Vaccine Research Center will use the company's technologies for vaccine development, including its production cell line, 293-ORF6, to design and test next-generation vaccines to optimize the body's immune response to HIV.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct